CRISPR Therapeutics, ViaCyte partner on diabetes therapies
In a deal worth up to $25 million for ViaCyte, the companies will work together to create allogeneic stem cell therapies to treat the disease.
Editas Medicines
In a deal worth up to $25 million for ViaCyte, the companies will work together to create allogeneic stem cell therapies to treat the disease.